-
Experienced Technology, Commercial, and Intellectual Property Attorney
For over 20 years, Mark has advised public and private companies, investors, and institutions on a variety of strategic technology, commercial, and intellectual property transactions, including strategic alliances, collaborations, licenses, joint ventures, and global supply chain, distribution, and commercialization structures.
-
A Focus on the Full Spectrum of Life Sciences Industries
His practice focuses on the pharmaceutical, biotechnology, diagnostic, digital health, and medical device industries.
-
Commitment to Clients at All Stages of the Business Life Cycle
Mark represents clients across the full spectrum of organizational development, from the largest global pharmaceutical companies to emerging biotechnology start-up companies.
Mark Bellomy is a partner in Wilson Sonsini Goodrich & Rosati’s Boston office, where he is a member of the technology transactions practice. Mark advises numerous domestic and international public and private biopharmaceutical, medtech, digital health, medical device, and life sciences companies on all of the transactions related to the discovery, development, supply, and commercialization of their products, technologies, and services. He counsels clients with respect to structuring and negotiating a wide range of arrangements designed to maximize the value of their businesses.
Mark specializes in working with his clients on the most complex strategic alliances and collaborations for the development and marketing of all stages of pharmaceutical and other products. In addition, he helps companies with a broad range of other transactions, including technology and asset acquisition, license, discovery, research, development (including clinical development), manufacture and supply, promotion, marketing, distribution, and services agreements. In 2022, Mark was recognized as a "Life Science Star" in the intellectual property section of LMG Life Sciences.
Prior to joining the firm, Mark was an IP transactions partner in the Boston office of another Am Law 100 firm. Earlier in his career, he was also senior licensing counsel for Wyeth Pharmaceuticals. Before attending law school, Mark served as a cavalry officer and scout platoon leader in the United States Army.
Mark Bellomy is a partner in Wilson Sonsini Goodrich & Rosati’s Boston office, where he is a member of the technology transactions practice. Mark advises numerous domestic and international public and private biopharmaceutical, medtech, digital health, medical device, and life sciences companies on all of the transactions related to the discovery, development, supply, and commercialization of their products, technologies, and services. He counsels clients with respect to structuring and negotiating a wide range of arrangements designed to maximize the value of their businesses.
Mark specializes in working with his clients on the most complex strategic alliances and collaborations for the development and marketing of all stages of pharmaceutical and other products. In addition, he helps companies with a broad range of other transactions, including technology and asset acquisition, license, discovery, research, development (including clinical development), manufacture and supply, promotion, marketing, distribution, and services agreements. In 2022, Mark was recognized as a "Life Science Star" in the intellectual property section of LMG Life Sciences.
Prior to joining the firm, Mark was an IP transactions partner in the Boston office of another Am Law 100 firm. Earlier in his career, he was also senior licensing counsel for Wyeth Pharmaceuticals. Before attending law school, Mark served as a cavalry officer and scout platoon leader in the United States Army.
- J.D., Harvard Law School
Magna Cum Laude
- B.S., Electrical Engineering, United States Military Academy at West Point
Distinguished Cadet, Phi Kappa Phi, Eta Kappa Nu
- Named among Managing IP’s “Transactions Stars” (2025)
- Named an "Unsung Hero" honoree for the New England Legal Awards (2025)
- Honored as a BTI Client Service All Star (2019)
- Recognized in Legal 500 (2013-2018)
- Named as a BTI Client Service All Stars MVP (2016)
- Recognized as lead outside counsel on the Pfizer-Merck KGaA anti-PD-L1 antibodies collaboration, a transaction that was honored as the 2015 “Deal of Distinction” in the Life Sciences category by the Licensing Executives Society
- State Bar of Massachusetts
- U.S. Patent and Trademark Office
- J.D., Harvard Law School
Magna Cum Laude
- B.S., Electrical Engineering, United States Military Academy at West Point
Distinguished Cadet, Phi Kappa Phi, Eta Kappa Nu
- Named among Managing IP’s “Transactions Stars” (2025)
- Named an "Unsung Hero" honoree for the New England Legal Awards (2025)
- Honored as a BTI Client Service All Star (2019)
- Recognized in Legal 500 (2013-2018)
- Named as a BTI Client Service All Stars MVP (2016)
- Recognized as lead outside counsel on the Pfizer-Merck KGaA anti-PD-L1 antibodies collaboration, a transaction that was honored as the 2015 “Deal of Distinction” in the Life Sciences category by the Licensing Executives Society
- State Bar of Massachusetts
- U.S. Patent and Trademark Office
Illustrative Representations
- Cue Biopharma in its collaboration and license agreement with ImmunoScape to advance a novel in vivo approach to cell therapy for the treatment of solid tumors
- Cue Biopharma in its license and collaboration with Boehringer Ingelheim for the development of next-generation treatments for autoimmune and inflammatory diseases
- Marengo Therapeutics in its collaborations with Ipsen for the development of T-cell engagers for the treatment of immunologically “cold tumors” and antibodies with T-cell costimulatory signals for the treatment of “hot tumors”
- Marengo Therapeutics in its clinical study collaboration with Gilead Sciences to explore combination therapies for the treatment of breast cancer
- Life Edit in its strategic collaboration with Moderna for the development of novel in-vivo gene editing therapies
- Agios Pharmaceuticals in its in-license of Alnylam’s siRNA blood disease program
- Elektrofi in its collaboration with Eli Lilly for the development of next-generation subcutaneously administered therapies
- Ji Xing Pharmaceuticals in its strategic partnership with TMS Co. for the development of novel antithrombotic agents for the treatment of acute ischemic stroke
- Pfizer in multiple early- and late-stage collaborations, including global collaborations with Merck KGaA (PD-L1 antibodies), MedGenesis Therapeutix (GDNF), Eli Lilly (MAb antinerve grow factors), and MSD International GmbH (SGLT-2 inhibitors)*
- Alexion Pharmaceuticals in multiple license and collaboration transactions, including its collaborations with Eidos Therapeutics and Affibody AB, and its option agreement with Stealth Biopharmaceuticals*
- AstraZeneca, Genzyme, Immunogen, Astellas, Biogen, AstraZeneca, Foundation Medicine, Catabasis, Waters, and other leading pharmaceutical, diagnostic, and medical technology companies in multiple collaboration, co-promotion, manufacturing, distribution, and commercialization relationships*
- Partners Healthcare in its licensing and implementation of the Epic Electronic Health Record platform*
- Development and implementation of licensing and collaboration best practices programs for multiple leading biopharmaceutical, medical device, and medical technology companies
* Denotes client experience from another firm prior to joining Wilson Sonsini in 2021.
Illustrative Representations
- Cue Biopharma in its collaboration and license agreement with ImmunoScape to advance a novel in vivo approach to cell therapy for the treatment of solid tumors
- Cue Biopharma in its license and collaboration with Boehringer Ingelheim for the development of next-generation treatments for autoimmune and inflammatory diseases
- Marengo Therapeutics in its collaborations with Ipsen for the development of T-cell engagers for the treatment of immunologically “cold tumors” and antibodies with T-cell costimulatory signals for the treatment of “hot tumors”
- Marengo Therapeutics in its clinical study collaboration with Gilead Sciences to explore combination therapies for the treatment of breast cancer
- Life Edit in its strategic collaboration with Moderna for the development of novel in-vivo gene editing therapies
- Agios Pharmaceuticals in its in-license of Alnylam’s siRNA blood disease program
- Elektrofi in its collaboration with Eli Lilly for the development of next-generation subcutaneously administered therapies
- Ji Xing Pharmaceuticals in its strategic partnership with TMS Co. for the development of novel antithrombotic agents for the treatment of acute ischemic stroke
- Pfizer in multiple early- and late-stage collaborations, including global collaborations with Merck KGaA (PD-L1 antibodies), MedGenesis Therapeutix (GDNF), Eli Lilly (MAb antinerve grow factors), and MSD International GmbH (SGLT-2 inhibitors)*
- Alexion Pharmaceuticals in multiple license and collaboration transactions, including its collaborations with Eidos Therapeutics and Affibody AB, and its option agreement with Stealth Biopharmaceuticals*
- AstraZeneca, Genzyme, Immunogen, Astellas, Biogen, AstraZeneca, Foundation Medicine, Catabasis, Waters, and other leading pharmaceutical, diagnostic, and medical technology companies in multiple collaboration, co-promotion, manufacturing, distribution, and commercialization relationships*
- Partners Healthcare in its licensing and implementation of the Epic Electronic Health Record platform*
- Development and implementation of licensing and collaboration best practices programs for multiple leading biopharmaceutical, medical device, and medical technology companies
* Denotes client experience from another firm prior to joining Wilson Sonsini in 2021.
- Privacy Policy
- Terms of Use
- Accessibility